Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Gastrointestinal 1

Conditions

Pancreatic Neoplasms 9Colorectal Neoplasms 8Colonic Neoplasms 6Rectal Neoplasms 4Breast Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Sarcoma 2Ovarian Neoplasms 2Multiple Myeloma 2Kidney Neoplasms 2Gallbladder Neoplasms 2Uterine Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Somatostatinoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Trastuzumab 2Temozolomide 2Capecitabine 2veliparib 1tipifarnib 1Panobinostat 1Oxaliplatin 1Melphalan 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Floxuridine 1Fentanyl 1Bortezomib 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulinoma × Bortezomib × Gastrointestinal × Clear all
NCT01056601 2017-12-28

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
7 enrolled 8 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡